Movement Disorders (revue)

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

Accuracy of acute levodopa challenge for clinical prediction of sustained long‐term levodopa response as a major criterion for idiopathic Parkinson's disease diagnosis

Identifieur interne : 004581 ( Main/Exploration ); précédent : 004580; suivant : 004582

Accuracy of acute levodopa challenge for clinical prediction of sustained long‐term levodopa response as a major criterion for idiopathic Parkinson's disease diagnosis

Auteurs : Marcelo Merello [Argentine] ; Maria I. Nouzeilles [Argentine] ; Gabriel Piran Arce [Argentine] ; Ram N Leiguarda [Argentine]

Source :

RBID : ISTEX:81B1ADEE0F70C967F4A693D91F53D3C80F6B9775

Descripteurs français

English descriptors

Abstract

Clinical idiopathic Parkinson's disease (PD) diagnosis requires following strict clinical criteria. Final definitive diagnosis can only be made after pathological confirmation and, despite following clinical criteria, several cases are misdiagnosed. We assessed sensitivity and specificity of acute challenge with levodopa (L‐dopa) to predict sustained long‐term L‐dopa responsiveness as a major criterion for clinical diagnosis of PD. A consecutive series of 82 patients first seen at a movement disorders clinic with a parkinsonian syndrome without specific diagnosis was included. A second examiner, blind to the presumptive diagnosis, performed in each patient an acute challenge with 250/50 mg of L‐dopa–carbidopa and rated the test as positive or negative according to whether values reached a minimal 30% of improvement on UPDRS scores. Positive tests were considered supportive of presumptive clinical diagnosis of Parkinson's disease. Blind to test results and according to clinical presumption, the first examiner started patient treatment with the necessary L‐dopa dose or, alternatively, until reaching 1 g for 1 month in those who failed to display a positive test response. At 24 month follow‐up, they were re‐tested with 1 g for 1 month when required. At this point, clinical criteria of the U.K. Parkinson's Disease Society Brain Bank were applied and definitive clinical diagnosis of PD was made. Sensitivity, specificity, and positive predictive ratio for acute challenge were calculated. Overall sensitivity and specificity of acute L‐dopa challenge to predict clinical diagnosis of PD was 70.9% and 81.4%, respectively; positive predictive ratio was 88.6%. When patients were divided into three groups according to their UPDRS motor section score at initial examination, sensitivity and specificity varied: Group I (≤ 10), 71.4% and 100%; Group II (11–20), 75% and 75%; and Group III (≥21), 36.4% and 87%, respectively. Positive predictive ratio increased to 100% in Group I and to 87.5% in Group III. The positive result of initial acute L‐dopa challenge predicts chronic L‐dopa responsiveness as major criterion of PD in all patients with UPDRS motor scores lower than 10. © 2002 Movement Disorder Society

Url:
DOI: 10.1002/mds.10123


Affiliations:


Links toward previous steps (curation, corpus...)


Le document en format XML

<record>
<TEI wicri:istexFullTextTei="biblStruct">
<teiHeader>
<fileDesc>
<titleStmt>
<title xml:lang="en">Accuracy of acute levodopa challenge for clinical prediction of sustained long‐term levodopa response as a major criterion for idiopathic Parkinson's disease diagnosis</title>
<author>
<name sortKey="Merello, Marcelo" sort="Merello, Marcelo" uniqKey="Merello M" first="Marcelo" last="Merello">Marcelo Merello</name>
</author>
<author>
<name sortKey="Nouzeilles, Maria I" sort="Nouzeilles, Maria I" uniqKey="Nouzeilles M" first="Maria I." last="Nouzeilles">Maria I. Nouzeilles</name>
</author>
<author>
<name sortKey="Arce, Gabriel Piran" sort="Arce, Gabriel Piran" uniqKey="Arce G" first="Gabriel Piran" last="Arce">Gabriel Piran Arce</name>
</author>
<author>
<name sortKey="Leiguarda, Ram N" sort="Leiguarda, Ram N" uniqKey="Leiguarda R" first="Ram N" last="Leiguarda">Ram N Leiguarda</name>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:81B1ADEE0F70C967F4A693D91F53D3C80F6B9775</idno>
<date when="2002" year="2002">2002</date>
<idno type="doi">10.1002/mds.10123</idno>
<idno type="url">https://api.istex.fr/document/81B1ADEE0F70C967F4A693D91F53D3C80F6B9775/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">001716</idno>
<idno type="wicri:Area/Istex/Curation">001716</idno>
<idno type="wicri:Area/Istex/Checkpoint">002E73</idno>
<idno type="wicri:doubleKey">0885-3185:2002:Merello M:accuracy:of:acute</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:12210878</idno>
<idno type="wicri:Area/PubMed/Corpus">003A08</idno>
<idno type="wicri:Area/PubMed/Curation">003A08</idno>
<idno type="wicri:Area/PubMed/Checkpoint">003C02</idno>
<idno type="wicri:Area/Ncbi/Merge">000843</idno>
<idno type="wicri:Area/Ncbi/Curation">000843</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">000843</idno>
<idno type="wicri:doubleKey">0885-3185:2002:Merello M:accuracy:of:acute</idno>
<idno type="wicri:Area/Main/Merge">006587</idno>
<idno type="wicri:source">INIST</idno>
<idno type="RBID">Pascal:02-0456874</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">002683</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000638</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">002867</idno>
<idno type="wicri:doubleKey">0885-3185:2002:Merello M:accuracy:of:acute</idno>
<idno type="wicri:Area/Main/Merge">006906</idno>
<idno type="wicri:Area/Main/Curation">004581</idno>
<idno type="wicri:Area/Main/Exploration">004581</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title level="a" type="main" xml:lang="en">Accuracy of acute levodopa challenge for clinical prediction of sustained long‐term levodopa response as a major criterion for idiopathic Parkinson's disease diagnosis</title>
<author>
<name sortKey="Merello, Marcelo" sort="Merello, Marcelo" uniqKey="Merello M" first="Marcelo" last="Merello">Marcelo Merello</name>
<affiliation wicri:level="1">
<country xml:lang="fr">Argentine</country>
<wicri:regionArea>Movement Disorders Section, Raul Carrea Institute for Neurological Research (FLENI), Buenos Aires</wicri:regionArea>
<wicri:noRegion>Buenos Aires</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Nouzeilles, Maria I" sort="Nouzeilles, Maria I" uniqKey="Nouzeilles M" first="Maria I." last="Nouzeilles">Maria I. Nouzeilles</name>
<affiliation wicri:level="1">
<country xml:lang="fr">Argentine</country>
<wicri:regionArea>Movement Disorders Section, Raul Carrea Institute for Neurological Research (FLENI), Buenos Aires</wicri:regionArea>
<wicri:noRegion>Buenos Aires</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Arce, Gabriel Piran" sort="Arce, Gabriel Piran" uniqKey="Arce G" first="Gabriel Piran" last="Arce">Gabriel Piran Arce</name>
<affiliation wicri:level="1">
<country xml:lang="fr">Argentine</country>
<wicri:regionArea>Movement Disorders Section, Raul Carrea Institute for Neurological Research (FLENI), Buenos Aires</wicri:regionArea>
<wicri:noRegion>Buenos Aires</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Leiguarda, Ram N" sort="Leiguarda, Ram N" uniqKey="Leiguarda R" first="Ram N" last="Leiguarda">Ram N Leiguarda</name>
<affiliation wicri:level="1">
<country xml:lang="fr">Argentine</country>
<wicri:regionArea>Movement Disorders Section, Raul Carrea Institute for Neurological Research (FLENI), Buenos Aires</wicri:regionArea>
<wicri:noRegion>Buenos Aires</wicri:noRegion>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series>
<title level="j">Movement Disorders</title>
<title level="j" type="abbrev">Mov. Disord.</title>
<idno type="ISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<imprint>
<publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher>
<pubPlace>New York</pubPlace>
<date type="published" when="2002-07">2002-07</date>
<biblScope unit="vol">17</biblScope>
<biblScope unit="issue">4</biblScope>
<biblScope unit="page" from="795">795</biblScope>
<biblScope unit="page" to="798">798</biblScope>
</imprint>
<idno type="ISSN">0885-3185</idno>
</series>
<idno type="istex">81B1ADEE0F70C967F4A693D91F53D3C80F6B9775</idno>
<idno type="DOI">10.1002/mds.10123</idno>
<idno type="ArticleID">MDS10123</idno>
</biblStruct>
</sourceDesc>
<seriesStmt>
<idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc>
<textClass>
<keywords scheme="KwdEn" xml:lang="en">
<term>Adult</term>
<term>Aged</term>
<term>Antiparkinson agent</term>
<term>Chemotherapy</term>
<term>Diagnosis</term>
<term>Dose-Response Relationship, Drug</term>
<term>Evolution</term>
<term>Female</term>
<term>Follow-Up Studies</term>
<term>Humans</term>
<term>Idiopathic</term>
<term>Levodopa</term>
<term>Levodopa (adverse effects)</term>
<term>Levodopa (diagnostic use)</term>
<term>Levodopa (therapeutic use)</term>
<term>Long term</term>
<term>Long-Term Care</term>
<term>L‐dopa test</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Neurologic Examination (drug effects)</term>
<term>Parkinson Disease (diagnosis)</term>
<term>Parkinson Disease (drug therapy)</term>
<term>Parkinson disease</term>
<term>Parkinson s disease</term>
<term>Pharmacologic test</term>
<term>Predictive Value of Tests</term>
<term>Predictive value</term>
<term>Prognosis</term>
<term>Sensitivity</term>
<term>Specificity</term>
<term>Treatment</term>
<term>acute challenge</term>
<term>diagnostic criteria</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en">
<term>Levodopa</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="diagnostic use" xml:lang="en">
<term>Levodopa</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en">
<term>Levodopa</term>
</keywords>
<keywords scheme="MESH" qualifier="diagnosis" xml:lang="en">
<term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en">
<term>Neurologic Examination</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en">
<term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" xml:lang="en">
<term>Aged</term>
<term>Dose-Response Relationship, Drug</term>
<term>Female</term>
<term>Follow-Up Studies</term>
<term>Humans</term>
<term>Long-Term Care</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Predictive Value of Tests</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr">
<term>Adulte</term>
<term>Antiparkinsonien</term>
<term>Chimiothérapie</term>
<term>Diagnostic</term>
<term>Epreuve pharmacologique</term>
<term>Evolution</term>
<term>Idiopathique</term>
<term>Long terme</term>
<term>Lévodopa</term>
<term>Parkinson maladie</term>
<term>Pronostic</term>
<term>Sensibilité</term>
<term>Spécificité</term>
<term>Traitement</term>
<term>Valeur prédictive</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr">
<term>Adulte</term>
</keywords>
</textClass>
<langUsage>
<language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front>
<div type="abstract" xml:lang="en">Clinical idiopathic Parkinson's disease (PD) diagnosis requires following strict clinical criteria. Final definitive diagnosis can only be made after pathological confirmation and, despite following clinical criteria, several cases are misdiagnosed. We assessed sensitivity and specificity of acute challenge with levodopa (L‐dopa) to predict sustained long‐term L‐dopa responsiveness as a major criterion for clinical diagnosis of PD. A consecutive series of 82 patients first seen at a movement disorders clinic with a parkinsonian syndrome without specific diagnosis was included. A second examiner, blind to the presumptive diagnosis, performed in each patient an acute challenge with 250/50 mg of L‐dopa–carbidopa and rated the test as positive or negative according to whether values reached a minimal 30% of improvement on UPDRS scores. Positive tests were considered supportive of presumptive clinical diagnosis of Parkinson's disease. Blind to test results and according to clinical presumption, the first examiner started patient treatment with the necessary L‐dopa dose or, alternatively, until reaching 1 g for 1 month in those who failed to display a positive test response. At 24 month follow‐up, they were re‐tested with 1 g for 1 month when required. At this point, clinical criteria of the U.K. Parkinson's Disease Society Brain Bank were applied and definitive clinical diagnosis of PD was made. Sensitivity, specificity, and positive predictive ratio for acute challenge were calculated. Overall sensitivity and specificity of acute L‐dopa challenge to predict clinical diagnosis of PD was 70.9% and 81.4%, respectively; positive predictive ratio was 88.6%. When patients were divided into three groups according to their UPDRS motor section score at initial examination, sensitivity and specificity varied: Group I (≤ 10), 71.4% and 100%; Group II (11–20), 75% and 75%; and Group III (≥21), 36.4% and 87%, respectively. Positive predictive ratio increased to 100% in Group I and to 87.5% in Group III. The positive result of initial acute L‐dopa challenge predicts chronic L‐dopa responsiveness as major criterion of PD in all patients with UPDRS motor scores lower than 10. © 2002 Movement Disorder Society</div>
</front>
</TEI>
<affiliations>
<list>
<country>
<li>Argentine</li>
</country>
</list>
<tree>
<country name="Argentine">
<noRegion>
<name sortKey="Merello, Marcelo" sort="Merello, Marcelo" uniqKey="Merello M" first="Marcelo" last="Merello">Marcelo Merello</name>
</noRegion>
<name sortKey="Arce, Gabriel Piran" sort="Arce, Gabriel Piran" uniqKey="Arce G" first="Gabriel Piran" last="Arce">Gabriel Piran Arce</name>
<name sortKey="Leiguarda, Ram N" sort="Leiguarda, Ram N" uniqKey="Leiguarda R" first="Ram N" last="Leiguarda">Ram N Leiguarda</name>
<name sortKey="Nouzeilles, Maria I" sort="Nouzeilles, Maria I" uniqKey="Nouzeilles M" first="Maria I." last="Nouzeilles">Maria I. Nouzeilles</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 004581 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 004581 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     ISTEX:81B1ADEE0F70C967F4A693D91F53D3C80F6B9775
   |texte=   Accuracy of acute levodopa challenge for clinical prediction of sustained long‐term levodopa response as a major criterion for idiopathic Parkinson's disease diagnosis
}}

Wicri

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024